newsfilter
← Latest News
ACCESS Newswire·

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

  • Jaguar Health, Inc. (NASDAQ:JAGX) announced voting results from its November 6, 2026 Special Meeting of Stockholders.
  • Six proposals were submitted to & approved by the company's stockholders at the meeting.
  • Detailed descriptions of the proposals are available in the definitive proxy statement filed with the SEC on October 8, 2026.
  • Jaguar Health develops novel proprietary prescription drugs derived from plants for complicated gastrointestinal disease states.
  • Napo Pharmaceuticals, Inc. & Napo Therapeutics S.p.A. focus on developing crofelemer powder for oral solution to treat rare gastrointestinal disorders, including microvillus inclusion disease & short bowel syndrome.
  • Magdalena Biosciences is a joint venture between Jaguar & Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative to develop plant-derived prescription medicines for mental health indications.
  • The press release includes forward-looking statements subject to risks, uncertainties, & assumptions, with Jaguar not planning to publicly update or revise these statements.
Company
Jaguar Health, Inc.
Keywords
Healthcare & Pharmaceutical, Shareholder Meeting